Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
NCT06846554

A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

Led by Apollo Therapeutics Ltd · Updated on 2026-05-11

48

Participants Needed

6

Research Sites

129 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796. The trial will be conducted in two parts: * Part A: Up to 36 adults with WHO Group 1 Pulmonary arterial hypertension (PAH). * Part B (optional): Up to 12 adults with WHO Group 3 - PH associated with ILD (PH-ILD).

CONDITIONS

Official Title

A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant must be 18 to 80 years of age inclusive
  • Diagnosed with pulmonary hypertension via right heart catheterisation at any time prior to screening
  • WHO Functional Class II or III
  • Participant has the CardioMEMS PA Sensor implanted
Not Eligible

You will not qualify if you...

  • Hospital admission related to pulmonary hypertension within 3 months prior to screening
  • Major surgical procedure within 3 months prior to screening unless fully recovered
  • Diagnosis of pulmonary hypertension due to HIV, portal hypertension, schistosomiasis, or uncorrected congenital heart disease
  • History of left-sided heart disease or significant cardiac disease
  • History of uncontrolled systemic hypertension
  • Estimated glomerular filtration rate (eGFR) less than or equal to 30 ml/min/1.73m2
  • Life expectancy less than 12 months as assessed by investigator
  • Diagnosed with malignancy within 5 years prior to enrollment
  • Contraindications to MRI or required diagnostic or sampling methods

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Hammersmith/Imperial Hospital

London, London, United Kingdom, W12 0HS

Actively Recruiting

2

Royal United Hospital Bath

Bath, United Kingdom

Actively Recruiting

3

Royal Papworth Hospital

Cambridge, United Kingdom

Actively Recruiting

4

Golden Jubilee Hospital

Clydebank, United Kingdom

Actively Recruiting

5

Royal Brompton Hospital

London, United Kingdom

Actively Recruiting

6

Sheffield Teaching Hospitals

Sheffield, United Kingdom

Actively Recruiting

Loading map...

Research Team

S

Sanjay Aggarwal, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Trial of "APL-9796'' in Adults With Pulmonary Hypertension | DecenTrialz